share_log

AbCellera Biologics (NASDAQ:ABCL) & MusclePharm (OTCMKTS:MSLP) Financial Contrast

AbCellera Biologics (NASDAQ:ABCL) & MusclePharm (OTCMKTS:MSLP) Financial Contrast

纳斯达克(纳斯达克股票代码:ABCL)和默斯克莱姆制药公司(场外交易代码:MSLP)财务对比
Defense World ·  2022/11/12 03:11

AbCellera Biologics (NASDAQ:ABCL – Get Rating) and MusclePharm (OTCMKTS:MSLP – Get Rating) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, institutional ownership, dividends, risk, earnings, analyst recommendations and valuation.

艾伯赛乐生物(纳斯达克:ABCL-GET Rating)和穆斯克尔帕姆(OTCMKTS:MSLP-GET Rating)都是医药公司,但哪只股票更好?我们将根据这两家公司的盈利能力、机构所有权、股息、风险、收益、分析师推荐和估值等方面的实力进行比较。

Valuation and Earnings

估值和收益

This table compares AbCellera Biologics and MusclePharm's revenue, earnings per share (EPS) and valuation.

该表格比较了AbCellera Biologics和MusclePharm的收入、每股收益(EPS)和估值。

Get
到达
AbCellera Biologics
AbCellera生物制品公司
alerts:
警报:
Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
AbCellera Biologics $375.20 million 10.36 $153.46 million $0.79 17.19
MusclePharm $50.04 million 0.07 -$12.87 million ($0.58) -0.17
总收入 价格/销售额比 净收入 每股收益 市盈率
AbCellera生物制品公司 3.752亿美元 10.36 1.5346亿美元 $0.79 17.19
穆斯克尔帕姆 5,004万美元 0.07 -1287万美元 ($0.58) -0.17

AbCellera Biologics has higher revenue and earnings than MusclePharm. MusclePharm is trading at a lower price-to-earnings ratio than AbCellera Biologics, indicating that it is currently the more affordable of the two stocks.

AbCellera Biologics的收入和收益比MusclePharm更高。MusclePharm的市盈率低于AbCellera Biologics,这表明它目前是两只股票中更负担得起的一只。

Analyst Ratings

分析师评级

This is a breakdown of current ratings for AbCellera Biologics and MusclePharm, as provided by MarketBeat.
这是由MarketBeat提供的AbCellera Biologics和MusclePharm的当前评级细目。
Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
AbCellera Biologics 0 0 6 0 3.00
MusclePharm 0 0 0 0 N/A
销售评级 保持评级 购买评级 强劲的买入评级 评级分数
AbCellera生物制品公司 0 0 6 0 3.00
穆斯克尔帕姆 0 0 0 0 不适用

AbCellera Biologics currently has a consensus price target of $28.40, indicating a potential upside of 109.13%. Given AbCellera Biologics' higher probable upside, analysts clearly believe AbCellera Biologics is more favorable than MusclePharm.

AbCellera Biologics目前的共识目标价为28.4美元,表明潜在上行空间为109.13%。考虑到AbCellera Biologics更有可能的上行空间,分析师们显然认为AbCellera Biologics比MusclePharm更有利。

Institutional and Insider Ownership

机构和内部人持股

44.4% of AbCellera Biologics shares are owned by institutional investors. Comparatively, 15.5% of MusclePharm shares are owned by institutional investors. 30.3% of AbCellera Biologics shares are owned by insiders. Comparatively, 60.7% of MusclePharm shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

AbCellera Biologics 44.4%的股份由机构投资者持有。相比之下,机构投资者持有MusclePharm 15.5%的股份。AbCellera Biologics 30.3%的股份由内部人士持有。相比之下,MusclePharm 60.7%的股份由内部人士持有。强大的机构持股表明,捐赠基金、大型基金管理公司和对冲基金相信,一家公司有望实现长期增长。

Profitability

盈利能力

This table compares AbCellera Biologics and MusclePharm's net margins, return on equity and return on assets.

此表比较了AbCellera Biologics和MusclePharm的净利润率、股本回报率和资产回报率。

Net Margins Return on Equity Return on Assets
AbCellera Biologics 41.17% 21.62% 16.54%
MusclePharm -38.51% N/A -169.56%
净利润率 股本回报率 资产回报率
AbCellera生物制品公司 41.17% 21.62% 16.54%
穆斯克尔帕姆 -38.51% 不适用 -169.56%

Volatility and Risk

波动性和风险

AbCellera Biologics has a beta of -0.54, meaning that its share price is 154% less volatile than the S&P 500. Comparatively, MusclePharm has a beta of 0.17, meaning that its share price is 83% less volatile than the S&P 500.

AbCellera Biologics的贝塔系数为-0.54,这意味着其股价的波动性比标准普尔500指数低154%。相比之下,MusclePharm的贝塔系数为0.17,这意味着其股价的波动性比标准普尔500指数低83%。

Summary

摘要

AbCellera Biologics beats MusclePharm on 11 of the 13 factors compared between the two stocks.

AbCellera Biologics在两只股票之间进行比较的13个因素中有11个击败了MusclePharm。

About AbCellera Biologics

关于AbCellera Biologics

(Get Rating)

(获取评级)

AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in progress, or under contract with 36 partners. AbCellera Biologics Inc. has a research collaboration and license agreement with Eli Lilly and Company. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.

AbCellera Biologics Inc.开发抗体发现平台。它的全栈、人工智能支持的抗体发现平台搜索和分析自然免疫系统的数据库,以发现可以开发为药物的抗体。截至2021年12月31日,该公司有156个已完成、正在进行或与36个合作伙伴签订合同的发现项目。AbCellera Biologics Inc.与礼来公司有研究合作和许可协议。该公司成立于2012年,总部位于加拿大温哥华。

About MusclePharm

关于MusclePharm

(Get Rating)

(获取评级)

MusclePharm Corporation develops, manufactures, markets, and distributes sports nutrition products and nutritional supplements in the United States and internationally. The company offers a range of performance powders, capsules, tablets, gels, and on-the-go ready to eat snacks. Its MusclePharm brand product portfolio includes combat protein powder and combat crunch protein bars; and essential supplements, such as a BCAA, creatine, glutamine, carnitine, CLA, fish oil, multi-vitamin, and other products. The company also provides FitMiss branded sports nutrition products, which are formulated primarily for the female body to support women in the areas of weight management, lean muscle mass, body composition, and general health and wellness; and functional energy beverages under the Combat Energy and FitMiss Energy brands. It sells its products to various athletes and fitness enthusiasts. The company was incorporated in 2006 and is based in Las Vegas, Nevada.

公司在美国和国际上开发、制造、营销和分销运动营养品和营养补充剂。该公司提供一系列高性能粉末、胶囊、片剂、凝胶和随时可用的零食。该公司的MusclePharm品牌产品组合包括战斗蛋白粉和战斗挤压蛋白棒;以及支链氨基酸、肌酸、谷氨酰胺、肉碱、共轭亚油酸、鱼油、多种维生素和其他产品等基本补充剂。该公司还提供FitMisse品牌的运动营养产品,这些产品主要是为女性身体制定的,以支持女性在体重管理、瘦肌肉质量、身体成分以及一般健康和健康方面的需求;以及FitMisse Energy和FitMisse Energy品牌的功能能量饮料。它向各种运动员和健身爱好者销售其产品。该公司成立于2006年,总部设在内华达州拉斯维加斯。

Receive News & Ratings for AbCellera Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbCellera Biologics and related companies with MarketBeat.com's FREE daily email newsletter.

接受AbCellera生物制品日报的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收AbCellera Biologics和相关公司的最新新闻和分析师评级的每日摘要。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发